| Project/Area Number |
16K14626
|
|---|
| Research Category |
Grant-in-Aid for Challenging Exploratory Research
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Tumor diagnostics
|
|---|
| Research Institution | Hyogo Medical University |
|---|
Principal Investigator |
Eguchi Ryoji 兵庫医科大学, 医学部, 助教 (00461088)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
若林 一郎 兵庫医科大学, 医学部, 教授 (70220829)
|
|---|
| Project Period (FY) |
2016-04-01 – 2018-03-31
|
| Project Status |
Completed (Fiscal Year 2017)
|
| Budget Amount *help |
¥3,770,000 (Direct Cost: ¥2,900,000、Indirect Cost: ¥870,000)
Fiscal Year 2017: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
Fiscal Year 2016: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
|
|---|
| Keywords | 血管新生 / 悪性中皮腫 / 血管内皮増殖因子 (VEGF) / granulin (GRN) / progranulin (PGRN) / VEGF / granulin / progranulin |
|---|
| Outline of Final Research Achievements |
Malignant mesothelioma is an aggressive tumor arising from the mesothelial cells of serous membranes including pleura, and is associated with tumor angiogenesis, which is prerequisite for tumor progression. Vascular endothelial growth factor-A (VEGF-A), one of VEGF family, plays a pivotal role in tumor angiogenesis. Bevacizumab, a monoclonal antibody to VEGF-A, has recently been reported to improve the overall survival of patients with malignant mesothelioma, but not the progression-free survival of them. These studies suggest VEGF-independent angiogenic factors in malignant mesothelioma, but the factors remained unknown. In the present study, we clarified that progranulin and granulin-like protein derived from granulin gene are novel VEGF-independent angiogenic factors in malignant mesothelioma.
|
